Standardizing Reporting for Patients Using Connected Insulin Pens and Continuous Glucose Monitoring

-A prototype one-page Dashboard summary may help standardize the reporting for patients with diabetes who take multiple daily injections of insulin via a connected insulin pen and continuous glucose monitoring. The reporting includes glucose, insulin, meals, and activity data for providers and patients, as described in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT). Click here to read the article now.

The one-page report includes metrics on glucose, including time below-, above-, and within-target ranges overall and by date, time of day, or day of the week. It also includes insulin metrics, including types and doses, and timing of basal and bolus insulin. Other metrics include an Ambulatory Glucose Profile, user experience, and clinical insights.

“We have presented a summary Dashboard report of glucose and insulin data for patients on MDI, using connected/memory insulin pens and CGM to identify clinical problems. This prototype is intended to stimulate development of a standardized, consensus-based summary report to meet the needs of the majority of insulin-requiring patients and their caregivers,” state coauthors David Rodbard, MD, Biomedical Informatics Consultants, and Satish Garg, MD, University of Colorado Anschutz Medical Campus and Editor-in-Chief of Diabetes Technology & Therapeutics.

About the Journal

Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, University of Colorado Denver (Aurora), the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.

About ATTD

The Advanced Technologies & Treatments for Diabetes Conference (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

/Public Release. This material comes from the originating organization/author(s)and may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.